Search Results

Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported first quarter 2024 financial results and provided a corporate update.

Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced that CFO Raphi Levy will present at the following investor conferences in May 2024.

Alpha Tau Medical Ltd. today announced that CFO Raphi Levy will present a corporate overview and update at the Jefferies Global Healthcare Conference on June 5 th , 2024.

Alpha Tau Medical Ltd. announced today that its first patient with liver cancer metastases has been treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada.

Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the presentation of new preclinical data at the 2024 congress of the European Society for Radiotherapy and Oncology (ESTRO).

Alpha Tau Medical today the publication of an article entitled “Extended Follow-Up Outcomes from Pooled Prospective Studies Evaluating Efficacy of Interstitial Alpha Radionuclide Treatment for Skin and Head and Neck Cancers” in the journal Cancers, with further detail on data previously announced by the Company in August 2023.

Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported full year 2023 financial results and provided a corporate update.